mRNA Revolution: SiSaf case study

SiSaf logo 355 x 200.jpg

SiSaf's Bio-Courier® technology uses bioabsorbable silicon to improve nucleic acid delivery. The company licenses the technology and develops its own RNA therapeutics, with a focus on rare genetic disorders and oncology. The mRNA Revolution: A new generation of medicine report highlights the effectiveness, safety, and versatility of SiSaf's sshLNPs compared to conventional LNPs.

What does the company do?

SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other nucleic acid delivery technologies through the hybridisation of organic materials with inorganic bioabsorbable silicon. The company’s business model is to maximise the potential of its technology by licensing to industry partners and by developing an in-house pipeline of RNA therapeutics. SiSaf’s most advanced programmes are RNA treatments for rare genetic disorders, but the company has the strategic ambition to expand its focus to other therapeutic areas, including oncology.

How does the technology work (simply)?

Lipid nanoparticles (LNP) have become the standard delivery system for mRNA. Bio-Courier® silicon stabilised lipid nanoparticles (sshLNP) are the next generation of lipid nanoparticles combining organic material – lipids – with inorganic material – bioabsorbable silicon. The silicon matrix stabilises both the lipid components and the RNA payload, reducing the need for ionisable or cationic lipids, PEGylated lipids, and cholesterol. This improves safety, targeting, and transfection. Unlike conventional lipid nanoparticles, sshLNP can be manufactured empty and loaded with the RNA later, at the desired point and time of use.

How is this an improvement on existing delivery technologies?

The stabilisation of both lipid components and RNA payload through silicon, as well as the ability to manufacture the carrier without RNA, overcome the key limitations of conventional LNP delivery systems for nucleic acid.

In conventional LNPs, the nucleic acid payload must be introduced early in the production process during the initial formation of LNPs prior to subsequent purification and fill/finish steps. This restricts batch sizes in commercial manufacturing due to the chemical lability of RNA, it affects the quality of the product that ultimately reaches the patient and requires an ultra-cold chain for storage and shipping.

In Bio-Courier sshLNPs, the nucleic acid can be introduced after the manufacture of the sshLNP particles. As a result, RNA encapsulation and fill/finish operations can be separated from carrier manufacture by considerable time and distance, readily permitting on-demand preparation of customised RNA-loaded LNPs on any scale.

In addition, Bio-Courier technology offers significant advantages over conventional LNP technology regarding stability, safety, targeting, and transfection.

  • Stability

The use of the positively charged silicon matrix to bind and stabilise the RNA payload reduces the need for cationic/ionisable lipids, avoiding the risk of premature leakage of RNA from the nanoparticles as the positive charge from the lipids decays. The improved physical stability also translates into improved transfection efficiency.

  • Safety

Existing approved LNPs rely on PEGylated lipids to protect RNA against enzymatic degradation, however, PEGylated lipids can induce anti-PEG antibodies and provoke an immune response. Due to their silicon-stabilised design, Bio-Courier sshLNPs are less reliant on PEGylated lipids than conventional LNPs, to the extent that some formulations are entirely free of PEGylation.

  • Targeting

LNPs have a strong tendency to accumulate in the liver. Biodistribution studies with Bio-Courier sshLNPs have demonstrated minimal accumulation in the liver and Bio-Courier formulations can be customised to provide controlled release and targeting of specific cells and tissues.

What are your challenges?

Opportunities for RNA medicines have advanced hugely in recent years. That being said, RNA remains a new modality with all of the associated development, manufacturing and regulatory challenges. SiSaf believe delivery technology helps move the field forward positively.

The patent landscape in RNA therapeutics including delivery platforms is complicated. However, SiSaf are confident of the strength of our IP (Intellectual Property) portfolio and both our freedom to operate and our ability to license our technology to others.

As a small but ambitious company, SiSaf needs to focus its resources on demonstrating the power of its technology and to attract external partnerships and investment to progress clinical programmes. We are proud that our lead programme SIS-101-ADO, an siRNA therapeutic for patients with Autosomal Dominant Osteopetrosis Type 2 (ADO2), has been granted both Orphan Drug Designation and Rare Pediatric Disease Designation by the U.S. FDA (Food and Drug Administration). There are currently no approved treatments for Osteopetrosis ADO2 and no other treatments currently in clinical trials.

If approved, SiSaf’s SIS-101-ADO would thus be the first treatment for Osteopetrosis ADO2 and could provide life-altering benefits for those who suffer from this debilitating disease. Their fast follower programme, SIS-102-ACH, would offer the first treatment of Achondroplasia that targets the genetic root cause of the condition. SiSaf also have partnered programmes to treat Type II Corneal Dystrophy and an undisclosed programme using Bio-Courier for topical delivery.

SiSaf have raised significant funding to date. They are committed to take their lead programmes through early clinical development, and thus anticipate a series C in due course.


More news and updates 

The UK's genomics sector: Poised for continued growth and impact

Genomics has become an integral part of the UK's healthcare system, revolutionising patient care and driving innovation within both small and medium-sized enterprises (SMEs) and large pharmaceutical companies. Our new report, Genomics nation 2023, highlights the profound impact of genomics on the UK's life sciences sector and public health system.

CEO Update - 4 December 2023

UK Biobank is a British success story that puts us at the heart of a key global technology of this century. Last week, UK Biobank published the world’s largest collection of full human genomes. Set up 20 years ago, the charity UK Biobank recruited half a million altruistic volunteers to create the world’s most comprehensive source of health data.

bioProcessUK 2023: Honouring excellence, unveiling future leaders 

In a symphony of innovation and camaraderie, the 20th anniversary bioProcessUK conference swept through Brighton, creating an unforgettable experience for the life sciences and biotech community.

CEO Update - 27 November 2023

Last week felt like an important milestone for the UK life science sector. As I sat in the Life Science Council in No 10 Downing Street with new Government Ministers, leaders of public institutions like the MHRA and global CEOs, I reflected that no other country in the world is putting together a working collaborative life science group like this.

bioProcessUK: The role of candidate screening and feasibility studies

Ian Goodwin, Director of CMC Program Design in Advanced Therapies (covering Cell and Gene Therapy services) at FUJIFILM Diosynth Biotechnologies explores the benefits of candidate and feasibility studies to AAV production.

Autumn Statement 2023 analysis

The Chancellor has delivered a comprehensive package of investment and support for the UK life sciences industry in his Autumn Statement. In this blog, Dr Martin Turner, Head of Policy and Public Affairs at BIA shares his reflections on key announcements.

Member spotlight: meet the Bio-Based and Biodegradable Industries Association

The Bio-Based and Biodegradable Industries Association (BBIA) and The BioIndustry Association (BIA) enter a mutual membership agreement to strengthen collaboration and support each other's work and member communities.

Bioprocessing: Unraveling the future by examining the past

Over the past two decades, the landscape of biopharmaceuticals in the UK has undergone a significant transformation.

CEO Update - 20 November 2023

London Life Sciences Week last week had an amazing buzz. I think there were more Americans in life science over for one week than I’ve ever experienced – centred on the Jefferies Healthcare Conference. At the same time, London was also full of Europeans at events like the Scrip Awards, where Jeremy Levin received the Lifetime Achievement Award and gave an impactful speech. The connectivity was immense - with a massive range of events that were really vibrant, diverse and inclusive.

London Life Sciences Week: connecting the global biotech community

London Life Sciences Week united the global biotech community for a dynamic week of networking and dealmaking. The BIA representatives were out and about throughout the week, networking with members and stakeholders. In this blog, Steve Bates OBE, CEO of BioIndustry Association, summarises insights based on the BIA team's first-hand experience.


More within